Birmingham and Lambeth Liver Evaluation Testing Strategies (BALLETS): a prospective cohort study

Objective: To evaluate mildly abnormal liver function test (LFT) results in general practice among patients who do not have known liver disease. Design: Prospective cohort study of people with abnormal LFT results identified in primary care. Participants were intensively investigated using a common...

Full description

Bibliographic Details
Main Authors: RJ Lilford, L Bentham, A Girling, I Litchfield, R Lancashire, D Armstrong, R Jones, T Marteau, J Neuberger, P Gill, R Cramb, S Olliff, D Arnold, K Khan, MJ Armstrong, DD Houlihan, PN Newsome, PJ Chilton, K Moons, D Altman
Format: Article
Language:English
Published: NIHR Journals Library 2013-07-01
Series:Health Technology Assessment
Subjects:
Online Access:https://doi.org/10.3310/hta17280
_version_ 1818478290019549184
author RJ Lilford
L Bentham
A Girling
I Litchfield
R Lancashire
D Armstrong
R Jones
T Marteau
J Neuberger
P Gill
R Cramb
S Olliff
D Arnold
K Khan
MJ Armstrong
DD Houlihan
PN Newsome
PJ Chilton
K Moons
D Altman
author_facet RJ Lilford
L Bentham
A Girling
I Litchfield
R Lancashire
D Armstrong
R Jones
T Marteau
J Neuberger
P Gill
R Cramb
S Olliff
D Arnold
K Khan
MJ Armstrong
DD Houlihan
PN Newsome
PJ Chilton
K Moons
D Altman
author_sort RJ Lilford
collection DOAJ
description Objective: To evaluate mildly abnormal liver function test (LFT) results in general practice among patients who do not have known liver disease. Design: Prospective cohort study of people with abnormal LFT results identified in primary care. Participants were intensively investigated using a common protocol and followed up for 2 years. Substudies investigated the psychological sequelae of abnormal test results, clinicians' reasons for testing, decision options when LFT results were abnormal and early detection of liver fibrosis. Setting: Eleven primary-care practices: eight in Birmingham and three in Lambeth. Participants: Adults with abnormal LFT results who did not have pre-existing or obvious liver disease. Eight analytes were included in the panel of LFTs. Main outcome measures: Statistical tests were used to identify the interactions between clinical features, the initial pattern of abnormal LFT results and (1) specific viral, genetic and autoimmune diseases, such as viral hepatitis, haemochromatosis and primary biliary cirrhosis; (2) a range of other serious diseases, such as metastatic cancer and hypothyroidism; (3) ‘fatty liver’ not associated with the above; and (4) the absence of detectable disease. Results: Fewer than 5% of people with abnormal LFT results had a specific disease of the liver, and many of these were unlikely to need treatment. The diagnostic potential of the LFT panel is largely subsumed into just two analytes: alanine aminotransferase (ALT) and alkaline phosphatase (ALP). Gamma-glutamyltransferase (GGT) offers a small increase in sensitivity at the margin at the cost of a large loss of specificity. Eighty-four per cent of abnormal LFT results remain abnormal on retesting 1 month later. In many cases, carrying out a definitive or specific test will be more efficient than repeating LFTs, with a view to specific testing only if the test remains abnormal. An ultrasound diagnosis of ‘fatty liver’ was present in nearly 40% of patients with abnormal LFTs and a small amount of weight loss over 2 years was associated with a reduced incidence of liver fat. There was a J-shaped relationship between alcohol intake and fatty liver in men. An abnormal LFT result causes temporary anxiety, which does not appear to promote sustained behaviour change. Conclusions: Liver disease is rare among people with abnormal LFT results in primary care. Only two analytes (ALT and ALP) are helpful in identifying the majority of liver disease. GGT adds little information in return for a high false-positive rate but it is sensitive to alcohol intake. LFT results seldom revert from abnormal to normal over a 1-month period, and modelling shows that repeating an abnormal LFT panel, as recommended in the current guidelines, is inefficient. LFTs are often undertaken to meet perceived patient need for a blood test, but as they are neither specific nor indicative of any particular disease they are among the least suitable tests for this purpose. Obesity and raised ALT provide strong evidence for a presumptive diagnosis of ‘fatty’ liver. Abnormal LFTs and ‘fatty’ liver provoke only short-term anxiety and neither is associated with sustained weight loss. Even a small amount of weight loss reduces liver fat. Future work recommendations: (1) the cases of ‘fatty liver’ and controls should be followed up in the long term to identify features that predict development of hepatosteatosis and then cirrhosis; (2) the acceptability of replacing the traditional six- to eight-analyte LFT panel with a drop down menu including the ALT/ALP combination should be evaluated. Funding: The National Institute for Health Research Health Technology Assessment programme.
first_indexed 2024-12-10T09:46:09Z
format Article
id doaj.art-5efd4c0b369345159f616aa3acc70408
institution Directory Open Access Journal
issn 1366-5278
2046-4924
language English
last_indexed 2024-12-10T09:46:09Z
publishDate 2013-07-01
publisher NIHR Journals Library
record_format Article
series Health Technology Assessment
spelling doaj.art-5efd4c0b369345159f616aa3acc704082022-12-22T01:53:50ZengNIHR Journals LibraryHealth Technology Assessment1366-52782046-49242013-07-01172810.3310/hta1728003/38/01Birmingham and Lambeth Liver Evaluation Testing Strategies (BALLETS): a prospective cohort studyRJ Lilford0L Bentham1A Girling2I Litchfield3R Lancashire4D Armstrong5R Jones6T Marteau7J Neuberger8P Gill9R Cramb10S Olliff11D Arnold12K Khan13MJ Armstrong14DD Houlihan15PN Newsome16PJ Chilton17K Moons18D Altman19School of Health and Population Sciences, University of Birmingham, Edgbaston, UKSchool of Health and Population Sciences, University of Birmingham, Edgbaston, UKSchool of Health and Population Sciences, University of Birmingham, Edgbaston, UKSchool of Health and Population Sciences, University of Birmingham, Edgbaston, UKSchool of Health and Population Sciences, University of Birmingham, Edgbaston, UKDepartment of Primary Care and Public Health Sciences, Kings College London, London, UKDepartment of Primary Care and Public Health Sciences, Kings College London, London, UKHealth Psychology Section, Kings College London, London, UKSchool of Health and Population Sciences, University of Birmingham, Edgbaston, UKSchool of Health and Population Sciences, University of Birmingham, Edgbaston, UKQueen Elizabeth Hospital Birmingham, Birmingham, UKQueen Elizabeth Hospital Birmingham, Birmingham, UKSchool of Medicine, Cardiff University, Cardiff, UKQueen Elizabeth Hospital Birmingham, Birmingham, UKNational Institute for Health Research Biomedical Research Unit, Birmingham, UKNational Institute for Health Research Biomedical Research Unit, Birmingham, UKNational Institute for Health Research Biomedical Research Unit, Birmingham, UKSchool of Health and Population Sciences, University of Birmingham, Edgbaston, UKUniversitair Medisch Centrum Utrecht, Utrecht, the NetherlandsCentre for Statistics in Medicine, University of Oxford, Oxford, UKObjective: To evaluate mildly abnormal liver function test (LFT) results in general practice among patients who do not have known liver disease. Design: Prospective cohort study of people with abnormal LFT results identified in primary care. Participants were intensively investigated using a common protocol and followed up for 2 years. Substudies investigated the psychological sequelae of abnormal test results, clinicians' reasons for testing, decision options when LFT results were abnormal and early detection of liver fibrosis. Setting: Eleven primary-care practices: eight in Birmingham and three in Lambeth. Participants: Adults with abnormal LFT results who did not have pre-existing or obvious liver disease. Eight analytes were included in the panel of LFTs. Main outcome measures: Statistical tests were used to identify the interactions between clinical features, the initial pattern of abnormal LFT results and (1) specific viral, genetic and autoimmune diseases, such as viral hepatitis, haemochromatosis and primary biliary cirrhosis; (2) a range of other serious diseases, such as metastatic cancer and hypothyroidism; (3) ‘fatty liver’ not associated with the above; and (4) the absence of detectable disease. Results: Fewer than 5% of people with abnormal LFT results had a specific disease of the liver, and many of these were unlikely to need treatment. The diagnostic potential of the LFT panel is largely subsumed into just two analytes: alanine aminotransferase (ALT) and alkaline phosphatase (ALP). Gamma-glutamyltransferase (GGT) offers a small increase in sensitivity at the margin at the cost of a large loss of specificity. Eighty-four per cent of abnormal LFT results remain abnormal on retesting 1 month later. In many cases, carrying out a definitive or specific test will be more efficient than repeating LFTs, with a view to specific testing only if the test remains abnormal. An ultrasound diagnosis of ‘fatty liver’ was present in nearly 40% of patients with abnormal LFTs and a small amount of weight loss over 2 years was associated with a reduced incidence of liver fat. There was a J-shaped relationship between alcohol intake and fatty liver in men. An abnormal LFT result causes temporary anxiety, which does not appear to promote sustained behaviour change. Conclusions: Liver disease is rare among people with abnormal LFT results in primary care. Only two analytes (ALT and ALP) are helpful in identifying the majority of liver disease. GGT adds little information in return for a high false-positive rate but it is sensitive to alcohol intake. LFT results seldom revert from abnormal to normal over a 1-month period, and modelling shows that repeating an abnormal LFT panel, as recommended in the current guidelines, is inefficient. LFTs are often undertaken to meet perceived patient need for a blood test, but as they are neither specific nor indicative of any particular disease they are among the least suitable tests for this purpose. Obesity and raised ALT provide strong evidence for a presumptive diagnosis of ‘fatty’ liver. Abnormal LFTs and ‘fatty’ liver provoke only short-term anxiety and neither is associated with sustained weight loss. Even a small amount of weight loss reduces liver fat. Future work recommendations: (1) the cases of ‘fatty liver’ and controls should be followed up in the long term to identify features that predict development of hepatosteatosis and then cirrhosis; (2) the acceptability of replacing the traditional six- to eight-analyte LFT panel with a drop down menu including the ALT/ALP combination should be evaluated. Funding: The National Institute for Health Research Health Technology Assessment programme.https://doi.org/10.3310/hta17280liver function testliver diseaseviral hepatitishaemochromatosisprimary biliary cirrhosisanalytealkaline phosphatasealanine aminotransferasefatty livercohort study
spellingShingle RJ Lilford
L Bentham
A Girling
I Litchfield
R Lancashire
D Armstrong
R Jones
T Marteau
J Neuberger
P Gill
R Cramb
S Olliff
D Arnold
K Khan
MJ Armstrong
DD Houlihan
PN Newsome
PJ Chilton
K Moons
D Altman
Birmingham and Lambeth Liver Evaluation Testing Strategies (BALLETS): a prospective cohort study
Health Technology Assessment
liver function test
liver disease
viral hepatitis
haemochromatosis
primary biliary cirrhosis
analyte
alkaline phosphatase
alanine aminotransferase
fatty liver
cohort study
title Birmingham and Lambeth Liver Evaluation Testing Strategies (BALLETS): a prospective cohort study
title_full Birmingham and Lambeth Liver Evaluation Testing Strategies (BALLETS): a prospective cohort study
title_fullStr Birmingham and Lambeth Liver Evaluation Testing Strategies (BALLETS): a prospective cohort study
title_full_unstemmed Birmingham and Lambeth Liver Evaluation Testing Strategies (BALLETS): a prospective cohort study
title_short Birmingham and Lambeth Liver Evaluation Testing Strategies (BALLETS): a prospective cohort study
title_sort birmingham and lambeth liver evaluation testing strategies ballets a prospective cohort study
topic liver function test
liver disease
viral hepatitis
haemochromatosis
primary biliary cirrhosis
analyte
alkaline phosphatase
alanine aminotransferase
fatty liver
cohort study
url https://doi.org/10.3310/hta17280
work_keys_str_mv AT rjlilford birminghamandlambethliverevaluationtestingstrategiesballetsaprospectivecohortstudy
AT lbentham birminghamandlambethliverevaluationtestingstrategiesballetsaprospectivecohortstudy
AT agirling birminghamandlambethliverevaluationtestingstrategiesballetsaprospectivecohortstudy
AT ilitchfield birminghamandlambethliverevaluationtestingstrategiesballetsaprospectivecohortstudy
AT rlancashire birminghamandlambethliverevaluationtestingstrategiesballetsaprospectivecohortstudy
AT darmstrong birminghamandlambethliverevaluationtestingstrategiesballetsaprospectivecohortstudy
AT rjones birminghamandlambethliverevaluationtestingstrategiesballetsaprospectivecohortstudy
AT tmarteau birminghamandlambethliverevaluationtestingstrategiesballetsaprospectivecohortstudy
AT jneuberger birminghamandlambethliverevaluationtestingstrategiesballetsaprospectivecohortstudy
AT pgill birminghamandlambethliverevaluationtestingstrategiesballetsaprospectivecohortstudy
AT rcramb birminghamandlambethliverevaluationtestingstrategiesballetsaprospectivecohortstudy
AT solliff birminghamandlambethliverevaluationtestingstrategiesballetsaprospectivecohortstudy
AT darnold birminghamandlambethliverevaluationtestingstrategiesballetsaprospectivecohortstudy
AT kkhan birminghamandlambethliverevaluationtestingstrategiesballetsaprospectivecohortstudy
AT mjarmstrong birminghamandlambethliverevaluationtestingstrategiesballetsaprospectivecohortstudy
AT ddhoulihan birminghamandlambethliverevaluationtestingstrategiesballetsaprospectivecohortstudy
AT pnnewsome birminghamandlambethliverevaluationtestingstrategiesballetsaprospectivecohortstudy
AT pjchilton birminghamandlambethliverevaluationtestingstrategiesballetsaprospectivecohortstudy
AT kmoons birminghamandlambethliverevaluationtestingstrategiesballetsaprospectivecohortstudy
AT daltman birminghamandlambethliverevaluationtestingstrategiesballetsaprospectivecohortstudy